Saturday, March 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Future of LLMs in Healthcare

In this episode, the host discusses the significance of large language models (LLMs) in healthcare, their applications, and the challenges they face. The conversation highlights the importance of simplicity in model design and the necessity of integrating patient feedback to enhance the effectiveness of LLMs in clinical settings.
Takeaways

  • LLMs are becoming integral in healthcare.
  • They can help determine costs and service options.
  • Hallucination in LLMs can lead to misinformation.
  • LLMs can produce inconsistent answers based on input.
  • Simplicity in LLMs is often more effective than complexity.
  • Patient behavior should guide LLM development.
  • Integrating patient feedback is crucial for accuracy.
  • Pre-training models with patient input enhances relevance.
  • Healthcare providers must understand LLM limitations.
  • The best LLMs will focus on patient-centered care.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!